#ariba_ref_name	ref_name	gene	var_only	flag	reads	cluster	ref_len	ref_base_assembled	pc_ident	ctg	ctg_len	ctg_cov	known_var	var_type	var_seq_type	known_var_change	has_known_var	ref_ctg_change	ref_ctg_effect	ref_start	ref_end	ref_nt	ctg_start	ctg_end	ctg_nt	smtls_total_depth	smtls_nts	smtls_nts_depth	var_description	free_text
16S.rDNA_WHO_F_01361c	16S.rDNA_WHO_F_01361c	0	1	19	2034	16S	1529	1529	100.0	16S.l15.c4.ctg.1	2272	205.8	1	SNP	n	C1184T	0	.	.	1184	1184	C	1406	1406	C	259	C,A,G	228,2,2	16S.rDNA_WHO_F_01361c:0:1:C1184T:16S.1184T:E coli C1192T. Resistance to Spectinomycin	.
23S.rDNA_WHO_F_01358c	23S.rDNA_WHO_F_01358c	0	1	531	3638	23S	2890	2890	99.9	23S.l15.c4.ctg.1	3958	214.9	0	.	n	.	0	T695C	SNP	695	695	T	1308	1308	C	284	C,A	248,2	.	.
23S.rDNA_WHO_F_01358c	23S.rDNA_WHO_F_01358c	0	1	531	3638	23S	2890	2890	99.9	23S.l15.c4.ctg.1	3958	214.9	0	.	n	.	0	G1337A	SNP	1337	1337	G	1950	1950	A	273	A,C,G	247,6,1	.	.
23S.rDNA_WHO_F_01358c	23S.rDNA_WHO_F_01358c	0	1	531	3638	23S	2890	2890	99.9	23S.l15.c4.ctg.1	3958	214.9	0	.	n	.	0	T1971C	SNP	1971	1971	T	2584	2584	C	233	C,A	210,1	.	.
23S.rDNA_WHO_F_01358c	23S.rDNA_WHO_F_01358c	0	1	531	3638	23S	2890	2890	99.9	23S.l15.c4.ctg.1	3958	214.9	1	SNP	n	A2045G	0	.	.	2045	2045	A	2658	2658	A	237	A,C,G	213,2,1	23S.rDNA_WHO_F_01358c:0:1:A2045G:23S.2045G:E coli A2059G. High-level resistance to Azithromycin	.
23S.rDNA_WHO_F_01358c	23S.rDNA_WHO_F_01358c	0	1	531	3638	23S	2890	2890	99.9	23S.l15.c4.ctg.1	3958	214.9	1	SNP	n	C2597T	0	.	.	2597	2597	C	3210	3210	C	242	C,A,T	216,2,1	23S.rDNA_WHO_F_01358c:0:1:C2597T:23S.2597T :E coli C2611T. Low-level resistance to Azithromycin	.
folP.WHO_V_01427c	folP.WHO_V_01427c	1	1	27	166	folP	855	855	100.0	folP.l15.c4.ctg.1	1688	21.9	1	SNP	p	R229S	1	.	.	685	687	AGC	1079	1081	AGC	20;20;16	A;G;C	18;17;14	folP.WHO_V_01427c:1:1:R229S:folP.228S:Resistance to sulphonamides	.
gyrA.WHO_M_01098	gyrA.WHO_M_01098	1	1	155	504	gyrA	2751	2751	100.0	gyrA.l15.c17.ctg.1	3772	31.3	1	SNP	p	S91F	1	.	.	271	273	TTC	860	862	TTC	28;28;28	T,G;T;C	25,2;23;26	gyrA.WHO_M_01098:1:1:S91F:gyrA.91F:Resistance to fluoroquinolones	.
gyrA.WHO_M_01098	gyrA.WHO_M_01098	1	1	155	504	gyrA	2751	2751	100.0	gyrA.l15.c17.ctg.1	3772	31.3	1	SNP	p	D95G	1	.	.	283	285	GGC	872	874	GGC	31;31;32	G,T;G;C,A	28,1;29;29,1	gyrA.WHO_M_01098:1:1:D95G:gyrA.95G:Resistance to fluoroquinolones	.
gyrA.WHO_M_01098	gyrA.WHO_M_01098	1	1	155	504	gyrA	2751	2751	100.0	gyrA.l15.c17.ctg.1	3772	31.3	1	SNP	p	G95N	0	.	.	283	285	GGC	872	874	GGC	31;31;32	G,T;G;C,A	28,1;29;29,1	gyrA.WHO_M_01098:1:1:G95N:gyrA.95N:Resistance to fluoroquinolones	.
gyrA.WHO_M_01098	gyrA.WHO_M_01098	1	1	155	504	gyrA	2751	2751	100.0	gyrA.l15.c17.ctg.1	3772	31.3	0	HET	.	.	.	G2374C,A	.	2374	2374	G	2963	2963	G	29	G,C,A	20,5,2	.	.
gyrA.WHO_M_01098	gyrA.WHO_M_01098	1	1	155	504	gyrA	2751	2751	100.0	gyrA.l15.c17.ctg.1	3772	31.3	0	HET	.	.	.	A562C,G	.	562	562	A	1151	1151	A	36	A,C,G	20,4,1	.	.
mtrR.WHO_L_00489c	mtrR.WHO_L_00489c	1	1	27	172	mtrR	633	633	100.0	mtrR.l15.c4.ctg.1	1615	25.2	1	SNP	p	G45D	1	.	.	133	135	GAC	568	570	GAC	48;48;48	G;A;C	44;44;43	mtrR.WHO_L_00489c:1:1:G45D:mtrR.45D:Increased efflux of antimicrobials, e.g. macrolides and b-lactam antimicrobials, that are substrates of the MtrCDE efflux pump	.
mtrR_promoter.WHO_F	mtrR_promoter.WHO_F	0	0	531	88	mtrR_promoter	250	250	99.6	mtrR_promoter.l15.c4.ctg.1	1313	14.7	0	.	n	.	0	A197.	DEL	197	197	A	747	747	A	32	A	28	.	.
parC.WHO_M_00204c	parC.WHO_M_00204c	1	1	539	364	parC	2304	2304	99.91	parC.l15.c17.ctg.1	2946	28.2	1	SNP	p	D86N	1	D86N	NONSYN	256	258	GAC	493	495	AAC	26;26;26	A;A;C,A	19;21;21,1	parC.WHO_M_00204c:1:1:D86N:parC.86N:Resistance to fluoroquinolones	.
parC.WHO_M_00204c	parC.WHO_M_00204c	1	1	539	364	parC	2304	2304	99.91	parC.l15.c17.ctg.1	2946	28.2	1	SNP	p	S87R	0	.	.	259	261	AGT	496	498	AGT	26;26;26	A,G;G;T,G	21,1;19;21,1	parC.WHO_M_00204c:1:1:S87R:parC.87R:Resistance to fluoroquinolones	.
parC.WHO_M_00204c	parC.WHO_M_00204c	1	1	539	364	parC	2304	2304	99.91	parC.l15.c17.ctg.1	2946	28.2	1	SNP	p	S87W	0	.	.	259	261	AGT	496	498	AGT	26;26;26	A,G;G;T,G	21,1;19;21,1	parC.WHO_M_00204c:1:1:S87W:parC.87W:Resistance to fluoroquinolones	.
parC.WHO_M_00204c	parC.WHO_M_00204c	1	1	539	364	parC	2304	2304	99.91	parC.l15.c17.ctg.1	2946	28.2	1	SNP	p	S87I	0	.	.	259	261	AGT	496	498	AGT	26;26;26	A,G;G;T,G	21,1;19;21,1	parC.WHO_M_00204c:1:1:S87I:parC.87I:Resistance to fluoroquinolones	.
parC.WHO_M_00204c	parC.WHO_M_00204c	1	1	539	364	parC	2304	2304	99.91	parC.l15.c17.ctg.1	2946	28.2	1	SNP	p	S88P	0	.	.	262	264	TCC	499	501	TCC	26;27;27	T;C,T;C	22;22,1;24	parC.WHO_M_00204c:1:1:S88P:parC.88P:Resistance to fluoroquinolones	.
parE.WHO_F_01528c	parE.WHO_F_01528c	1	1	27	352	parE	1986	1986	100.0	parE.l15.c4.ctg.1	3130	27.2	1	SNP	p	G410V	0	.	.	1228	1230	GGC	1841	1843	GGC	23;23;23	G,C;G,T;C	22,1;19,1;19	parE.WHO_F_01528c:1:1:G410V:parE.410V:Resistance to fluoroquinolones	.
penA.13.001	penA.13.001	1	1	27	398	penA	1749	1749	100.0	penA.l15.c4.ctg.1	2538	36.1	1	SNP	p	A311V	0	.	.	931	933	GCA	1519	1521	GCA	49;50;49	G;C,T;A,T	44;43,1;44,1	penA.13.001:1:1:A311V:penA.311V:Resistance to Extended-Spectrum Cephalosporins (ESCs)	.
penA.13.001	penA.13.001	1	1	27	398	penA	1749	1749	100.0	penA.l15.c4.ctg.1	2538	36.1	1	SNP	p	I312M	0	.	.	934	936	ATC	1522	1524	ATC	49;49;49	A;T,C;C	44;47,1;48	penA.13.001:1:1:I312M:penA.312M:Resistance to Extended-Spectrum Cephalosporins (ESCs)	.
penA.13.001	penA.13.001	1	1	27	398	penA	1749	1749	100.0	penA.l15.c4.ctg.1	2538	36.1	1	SNP	p	V316T	0	.	.	946	948	GTG	1534	1536	GTG	49;49;49	G,C;T,G;G	41,1;45,1;46	penA.13.001:1:1:V316T:penA.316T:Resistance to Extended-Spectrum Cephalosporins (ESCs)	.
penA.13.001	penA.13.001	1	1	27	398	penA	1749	1749	100.0	penA.l15.c4.ctg.1	2538	36.1	1	SNP	p	V316P	0	.	.	946	948	GTG	1534	1536	GTG	49;49;49	G,C;T,G;G	41,1;45,1;46	penA.13.001:1:1:V316P:penA.316P:Resistance to Extended-Spectrum Cephalosporins (ESCs)	.
penA.13.001	penA.13.001	1	1	27	398	penA	1749	1749	100.0	penA.l15.c4.ctg.1	2538	36.1	1	SNP	p	T484S	0	.	.	1450	1452	ACC	2038	2040	ACC	41;42;42	A,C;C;C	31,2;36;37	penA.13.001:1:1:T484S:penA.483S:Resistance to Extended-Spectrum Cephalosporins (ESCs)	.
penA.13.001	penA.13.001	1	1	27	398	penA	1749	1749	100.0	penA.l15.c4.ctg.1	2538	36.1	1	SNP	p	A502V	1	.	.	1504	1506	GTG	2092	2094	GTG	30;30;30	G;T,G;G,T	25;21,2;23,1	penA.13.001:1:1:A502V:penA.501V:Resistance to Extended-Spectrum Cephalosporins (ESCs)	.
penA.13.001	penA.13.001	1	1	27	398	penA	1749	1749	100.0	penA.l15.c4.ctg.1	2538	36.1	1	SNP	p	V502P	0	.	.	1504	1506	GTG	2092	2094	GTG	30;30;30	G;T,G;G,T	25;21,2;23,1	penA.13.001:1:1:V502P:penA.501P:Resistance to Extended-Spectrum Cephalosporins (ESCs)	.
penA.13.001	penA.13.001	1	1	27	398	penA	1749	1749	100.0	penA.l15.c4.ctg.1	2538	36.1	1	SNP	p	G543S	0	.	.	1627	1629	GGC	2215	2217	GGC	25;25;25	G,T;G,T;C,T	22,1;20,2;20,2	penA.13.001:1:1:G543S:penA.542S:Resistance to Extended-Spectrum Cephalosporins (ESCs)	.
penA.13.001	penA.13.001	1	1	27	398	penA	1749	1749	100.0	penA.l15.c4.ctg.1	2538	36.1	1	SNP	p	G546S	0	.	.	1636	1638	GGC	2224	2226	GGC	22;23;22	G;G;C,G	18;13;11,2	penA.13.001:1:1:G546S:penA.545S:Resistance to Extended-Spectrum Cephalosporins (ESCs)	.
penA.13.001	penA.13.001	1	1	27	398	penA	1749	1749	100.0	penA.l15.c4.ctg.1	2538	36.1	1	SNP	p	P552S	1	.	.	1654	1656	TCG	2242	2244	TCG	25;25;25	T;C;G	16;19;20	penA.13.001:1:1:P552S:penA.551S:Resistance to Extended-Spectrum Cephalosporins (ESCs)	.
ponA.WHO_G_00106	ponA.WHO_G_00106	1	1	27	628	ponA	2397	2397	100.0	ponA.l15.c4.ctg.1	3483	41.2	1	SNP	p	L421P	1	.	.	1261	1263	CCG	1818	1820	CCG	56;56;55	C,T,A;C;G,C	40,1,1;47;40,1	ponA.WHO_G_00106:1:1:L421P:ponA.421P:High-level chromosomally-mediated penicillin resistance	.
porA.NCCP11945	porA.NCCP11945	1	0	531	220	porA	1146	1146	99.74	porA.l6.c4.ctg.1	2173	23.8	0	.	p	.	0	A17T	NONSYN	49	51	GCA	492	494	ACA	29;29;29	A;C;A	24;23;24	.	.
porA.NCCP11945	porA.NCCP11945	1	0	531	220	porA	1146	1146	99.74	porA.l6.c4.ctg.1	2173	23.8	0	.	p	.	0	S22G	NONSYN	64	66	AGC	507	509	GGC	30;30;30	G;G;C	26;26;26	.	.
porA.NCCP11945	porA.NCCP11945	1	0	531	220	porA	1146	1146	99.74	porA.l6.c4.ctg.1	2173	23.8	0	.	p	.	0	M83fs	FSHIFT	247	247	A	689	689	C	17	C	13	.	.
porB1b.WHO_M_02204c	porB1b.WHO_M_02204c	1	1	539	316	porB1b	1041	1041	98.08	porB1b.l6.c4.ctg.1	2150	34.5	0	.	p	.	0	E48G	NONSYN	142	144	GAA	643	645	GGA	42;42;42	G,C;G;A,G,C	40,1;37;38,1,1	.	.
porB1b.WHO_M_02204c	porB1b.WHO_M_02204c	1	1	539	316	porB1b	1041	1041	98.08	porB1b.l6.c4.ctg.1	2150	34.5	0	.	p	.	0	T87A	NONSYN	259	261	ACT	760	762	GCT	52;51;52	G,T;C;T,G	44,1;44;48,2	.	.
porB1b.WHO_M_02204c	porB1b.WHO_M_02204c	1	1	539	316	porB1b	1041	1041	98.08	porB1b.l6.c4.ctg.1	2150	34.5	0	.	p	.	0	T89S	NONSYN	265	267	ACC	766	768	AGC	52;52;52	A;G,C;C,A,G	46;45,1;46,1,1	.	.
porB1b.WHO_M_02204c	porB1b.WHO_M_02204c	1	1	539	316	porB1b	1041	1041	98.08	porB1b.l6.c4.ctg.1	2150	34.5	0	.	p	.	0	K143Q	NONSYN	427	429	AAA	928	930	CAA	60;60;60	C;A;A,C	54;52;50,2	.	.
porB1b.WHO_M_02204c	porB1b.WHO_M_02204c	1	1	539	316	porB1b	1041	1041	98.08	porB1b.l6.c4.ctg.1	2150	34.5	0	.	p	.	0	V151A	NONSYN	451	453	GTA	952	954	GCA	59;59;59	G;C,A;A	54;50,1;49	.	.
porB1b.WHO_M_02204c	porB1b.WHO_M_02204c	1	1	539	316	porB1b	1041	1041	98.08	porB1b.l6.c4.ctg.1	2150	34.5	0	.	p	.	0	R187Q	NONSYN	559	561	CGA	1060	1062	CAA	41;41;41	C;A;A	39;39;39	.	.
porB1b.WHO_M_02204c	porB1b.WHO_M_02204c	1	1	539	316	porB1b	1041	1041	98.08	porB1b.l6.c4.ctg.1	2150	34.5	0	.	p	.	0	N189S	NONSYN	565	567	AAC	1066	1068	AGC	39;39;39	A;G;C	35;35;35	.	.
porB1b.WHO_M_02204c	porB1b.WHO_M_02204c	1	1	539	316	porB1b	1041	1041	98.08	porB1b.l6.c4.ctg.1	2150	34.5	0	.	p	.	0	Y212fs	FSHIFT	634	634	T	1135	1135	T	43	T	42	.	.
porB1b.WHO_M_02204c	porB1b.WHO_M_02204c	1	1	539	316	porB1b	1041	1041	98.08	porB1b.l6.c4.ctg.1	2150	34.5	1	SNP	p	G120K	1	.	.	358	360	AAG	859	861	AAG	51;51;50	A,C;A,T;G,T	48,1;48,1;47,1	porB1b.WHO_M_02204c:1:1:G120K:porB1b.120K:G101K. Mediates decreased permeability of antimicrobials through the porin PorB1b	.
porB1b.WHO_M_02204c	porB1b.WHO_M_02204c	1	1	539	316	porB1b	1041	1041	98.08	porB1b.l6.c4.ctg.1	2150	34.5	1	SNP	p	D121N	0	.	.	361	363	GAC	862	864	GAC	50;49;49	G;A;C,A	48;46;46,1	porB1b.WHO_M_02204c:1:1:D121N:porB1b.121N:A102N. Mediates decreased permeability of antimicrobials through the porin PorB1b	.
porB1b.WHO_M_02204c	porB1b.WHO_M_02204c	1	1	539	316	porB1b	1041	1041	98.08	porB1b.l6.c4.ctg.1	2150	34.5	1	SNP	p	A121D	1	.	.	361	363	GAC	862	864	GAC	50;49;49	G;A;C,A	48;46;46,1	porB1b.WHO_M_02204c:1:1:A121D:porB1b.121D:A102D. Mediates decreased permeability of antimicrobials through the porin PorB1b	.
rpoB.WHO_F_02153c	rpoB.WHO_F_02153c	1	1	539	1056	rpoB	4179	4179	99.98	rpoB.l6.c4.ctg.1	5291	47.1	1	SNP	p	H553N	1	H553N	NONSYN	1657	1659	CAT	2207	2209	AAT	48;48;48	A;A;T	45;45;45	rpoB.WHO_F_02153c:1:1:H553N:rpoB.553N:H552N. High-level resistance to Rifampicin	.
rpsJ.WHO_Y_02241	rpsJ.WHO_Y_02241	1	1	27	138	rpsJ	312	312	100.0	rpsJ.l6.c17.ctg.1	1248	26.5	1	SNP	p	V57M	1	.	.	169	171	ATG	666	668	ATG	46;46;46	A;T;G	41;43;43	rpsJ.WHO_Y_02241:1:1:V57M:rpsJ.57M:Chromosomally-mediated resistance to tetracyclines	.
